

Evolution of brachytherapy in providing conformal plans – from 2D to 3D IGABT, IPSA and HIPO



Dr. Abhishek Basu
MD, DNB, PDCR

***Assistant Professor, Department of Radiation Oncology,
Burdwan Medical College, Purba Bardhaman
ESTRO Teaching Faculty for Gynecological Brachytherapy***

Disclosures & Acknowledgements


- *Teaching Faculty for the ESTRO GYN TCs (2016 onwards).*
- *Certified International trainer for Gyn Brachy by Eckert and Ziegler Bebig GmBH.*
- *Co-author : IBS Guidelines for Cervical Cancer and Member Co-ordination Committee of AROI for AROI ESTRO Gyn TCs.*
- *Teaching material from GYN GEC ESTRO Teaching Courses (2012 – 2020).*
- *Prof. Richard Poetter, Prof. Kari Tanderup, Prof. Christine Haie Meder, Prof. Umesh Mahantshetty and Prof. Jamema Swamidas.*
- *Present and previous faculty members, residents, nursing personnel and staff at The Departments of Radiation Oncology, RGKMCH, Kolkata and BMCH, Burdwan.*

BRACHYTHERAPY : WHAT?

EBRT vs BT




BURDWAN
MEDICAL COLLEGE




Advantages of BT

- Conforms to irregular tumor volumes.
- Avoids geographical miss - moves with the tumor.
- Rapid dose fall off.
- Center of tumor (hypoxic / radio-resistant area) actually receives much higher dose.




BRACHYTHERAPY IN CARCINOMA CERVIX : WHY?

Advantages of BT : Eg : Cervix



Advantages of BT : Eg : Cervix









BRACHYTHERAPY : EVOLUTION


Journey from 2D to 3D



BURDWAN
MEDICAL COLLEGE




Journey from 2D to 3D







BRACHYTHERAPY : EVOLUTION IMAGING

2D Orthogonal X-ray based concept



Assessment modalities

	Clinical	USG	CT	MRI
Availability				
Cost				
Standard	<i>Gold</i>	<i>Silver+</i>	<i>Silver</i>	<i>Gold</i>

	Pre EBRT Correlation (Pearson's correlation coefficients)		
	MRI-CLINICAL	MRI-USG	MRI-CT
Antero-Posterior	0.48	0.49	0.73
Medio-Lateral	0.18	0.14	0.62
Supero-Inferior	0.23	0.45	0.66

Journey from 2D to 3D

The GYN GEC ESTRO I – IV recommendations



Radiotherapy and Oncology 74 (2005) 235–245



www.elsevier.com/locate/radonline

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group[☆] (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV

Christine Haie-Meder^{a,*}, Richard Pötter^b, Erik Van Limbergen^c, Edith Briot^a,

Radiotherapy and Oncology 78 (2006) 67–77
www.thegreenjournal.com

ESTRO project

Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology

Richard Pötter^{a,*}, Christine Haie-Meder^b, Erik Van Limbergen^c, Isabelle Barillot^d,


Radiotherapy and Oncology 96 (2010) 153–160



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



GEC-ESTRO Recommendations

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy

Taran Paulsen Hellebust^{a,*}, Christian Kirisits^b, Daniel Berger^b, José Pérez-Calatayud^c,

Radiotherapy and Oncology 103 (2012) 113–122



Contents lists available at SciVerse ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



GEC-ESTRO Recommendations

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy

Johannes C.A. Dimopoulos^a, Peter Petrow^b, Kari Tanderup^c, Primoz Petric^d, Daniel Berger^e,

Journey from 2D to 3D

The Indian Brachytherapy Society recommendations

Educational Article

Original paper

Indian Brachytherapy Society Guidelines for radiotherapeutic management of cervical cancer with special emphasis on high-dose-rate brachytherapy

Umesh Mahantshetty, MD¹, Shivakumar Gudi, MD¹, Roshni Singh, MD¹, Ajay Sasidharan, MD¹,
Supriya (Chopra) Sastri, MD¹, Lavanya Gurram, MD¹, Dayanand Sharma, MD², Selvaluxmy Ganeshrajah, MD³,
Janaki MG, MD⁴, Dinesh Badakh, MD⁵, Abhishek Basu, MD⁶, Francis James, MD⁷, Jamema V Swamidas, PhD⁸,
Thayalan Kuppuswamy, PhD⁹, Rajendra Bhalavat, MD¹⁰

¹Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, ²Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India, ³Department of Gynecology Oncology, Cancer Institute (WIA), Chennai, India, ⁴Department of Radiation Oncology, M.S. Ramaiah Memorial Hospital, Bangalore, India, ⁵Department of Radiation Oncology, Siddhivinayak Cancer Hospital, Miraj, India, ⁶Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India, ⁷Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, India, ⁸Department of Medical Physics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, ⁹Medical Physics Division, Dr. Kamakshi Memorial Hospital, Chennai, India, ¹⁰Department of Radiation Oncology, Jupiter Hospital, Mumbai, India

MRI protocol



BURDWAN
MEDICAL COLLEGE





Table 1

Image acquisition protocols for pre-RT MRI scan and BT MRI scan. This table summarises the important information regarding sequence, plane orientation, coverage/borders for each of the different MRI sequences.

Protocol	Number	Mandatory (M)/ optional (O)	Sequence	Plane orientation	Coverage/borders
Pre-RT MRI scan	1	M	T2 FSE	Para-axial (according to cervix uteri)	Above uterine corpus – inferior border of symphysis pubis/entire vagina if distal vaginal involvement
	2	M	T2 FSE	Sagittal	Pelvic side wall (obturator muscle)
	3	M	T2 FSE	Para-coronal (according to cervix uteri)	Uterine corpus – cervix – vagina – tumour
	4	M	T2 FSE	Axial	Discus L4–L5 – inferior border of symphysis pubis/entire vagina and inguinal regions if distal vaginal involvement
	5	O	T1 FSE or 3D GRE without contrast ^a	Axial	Discus L4–L5 – inferior border of symphysis pubis/entire vagina and inguinal regions if distal vaginal involvement
	6	O	T1 FSE with contrast ^a	Sagittal	Pelvic side wall (obturator muscle)
	7	O	T1 FSE or 3D GRE with contrast ^a	Axial (isotropic 3D GRE)	Uterine corpus – cervix – vagina – tumour
BT MRI scan	8	M	T2 FSE	Para-axial (according to cervix uteri)	Above uterine corpus – 3 cm below lower surface of vaginal applicator/entire vagina if distal vaginal involvement
	9	M	T2 FSE	Para-sagittal (according to cervix uteri)	Pelvic side wall (obturator muscle)
	10	M	T2 FSE	Para-coronal (according to cervix uteri)	Uterine corpus – cervix – vagina – tumour
	11	O	T2 FSE	Axial	Above uterine corpus – 3 cm below lower surface of vaginal applicator/entire vagina if distal vaginal involvement
	12	O	3D T2 FSE isotropic	Coronal or axial with reconstructions	Large coverage inherent in this sequence
	13	O	T1 FSE, FLASH, T1 GRE 3D	As appropriate	At least entire applicator

^a When contrast series are applied (6 and/or 7); use same T1 sequence for pre-contrast and lymph node evaluation.

- T2w FSE sequences
- Vaginal jelly
- Para images

Different 3D environments

Environments	At diagnosis	Before Brachytherapy	At Brachytherapy
MR – MR	MR + Clinical	Clinical \pm MR	MR* + Clinical
MR – CT	MR + Clinical	MR + Clinical	CT* + Clinical
CT – CT	CT + Clinical	Clinical \pm CT	CT + Clinical

* - at least for the first fraction


CT Imaging protocol

- Bladder filling with dilute contrast.
- IV contrast – arterial phase – blush!
- Axial 2-3 mm slices.
- MR compatible applicators.



CT based target delineation


Radiotherapy and Oncology 160 (2021) 273–284



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



BURDWAN
MEDICAL COLLEGE

Original Article

IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer

Umesh Mahantshetty^{a,*}, Richard Poetter^{b,*}, Sushil Beriwal^c, Surbhi Grover^d, Gurram Lavanya^e, Bhavana Rai^f, Primož Petric^g, Kari Tanderup^h, Heloisa Carvalho^{ij}, Neamat Hegazy^k, Sandy Mohamed^l, Tatsuya Ohno^m, Napapat Amornwicheeⁿ



Patient Initials : ID :

	Infiltrative	Exophytic
Cervix	●	●
Vagina	●	●
Parametria	●	●
Rectum or Bladder	●	●

☐ Initial evaluation
☐ At brachy (fraction no.)

h = cm t = cm NMD (R) = cm NMD (L) = cm w = cm (NMD = Near Maximum Distance)

Vaginal Disease

Ant : cm
Post : cm
Rt Lat : cm
Lt Lat : cm

FIGO (2018)

T N M ()

BT_{category}: I_{BT}/II_{BT}/III_{BT}/IV_{BT}

Remarks:

Signature & Date :

CT_{DG} – CT_{BT} Environment




Fig. 2. Schematic diagram showing definition of CTV-T_{HR-CT} for CT_{DG} – CT_{BT} Environment based on the disease at diagnosis (cervix and parametrium in blue fill & vaginal disease in green lines), residual disease at BT (blue oblique lines), CTV-T_{HR} (in red continuous lines) and safety margins (red dotted lines). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journey from 2D to 3D

The Indian Brachytherapy Society recommendations


Educational Article

Original paper

Indian Brachytherapy Society Guidelines for radiotherapeutic management of cervical cancer with special emphasis on high-dose-rate brachytherapy


Umesh Mahantshetty, MD¹, Shivakumar Gudi, MD¹, Roshni Singh, MD¹, Ajay Sasidharan, MD¹,
Supriya (Chopra) Sastri, MD¹, Lavanya Gurram, MD¹, Dayanand Sharma, MD², Selvaluxmy Ganeshrajah, MD³,
Janaki MG, MD⁴, Dinesh Badakh, MD⁵, Abhishek Basu, MD⁶, Francis James, MD⁷, Jamema V Swamidas, PhD⁸,
Thayalan Kuppuswamy, PhD⁹, Rajendra Bhalavat, MD¹⁰

¹Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, ²Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India, ³Department of Gynecology Oncology, Cancer Institute (WIA), Chennai, India, ⁴Department of Radiation Oncology, M.S. Ramaiah Memorial Hospital, Bangalore, India, ⁵Department of Radiation Oncology, Siddhivinayak Cancer Hospital, Miraj, India, ⁶Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India, ⁷Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, India, ⁸Department of Medical Physics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, ⁹Medical Physics Division, Dr. Kamakshi Memorial Hospital, Chennai, India, ¹⁰Department of Radiation Oncology, Jupiter Hospital, Mumbai, India



T2w MRI


CT



Documentation

At Diagnosis

- Mrs. MS, 66 yr, HTN, white discharge with spotting 4 months.





At Diagnosis ☒

Stage FIGO IIB


w = 5 cm
h = 4.5 cm
t = 3 cm

Vagina: 2.5 cm
10 o'clock to 2 o'clock




Case MR ; Name : MS RT/2190/18

Adaptive MRI based planning : 4D RT



TRUS Guided Prostate Brachytherapy : 4D






BRACHYTHERAPY : EVOLUTION TARGET CONCEPTS

The concept of Point A and B





- Lateral throw-off of dose
- Obturator node
- Nodal dose ~ 3Gy for 4
- # of 7 Gy each




Modifications of Point A



BURDWAN
MEDICAL COLLEGE




The ICRU Bladder and Rectal Points




GYN GEC ESTRO concepts



BURDWAN
MEDICAL COLLEGE



ICRU 89 concepts : CTV



Morbidity related anatomical reference points and volumes for important OARs





Figure 6.4. Schematic anatomical diagrams (sagittal view) showing two different positions of the vaginal part of the utero-vaginal applicators, the cervix tumor, the uterus, and the reference volumes of OARs in two different patients. The most irradiated-tissue volumes adjacent to the applicator, *i.e.*, the reference volumes 0.1 cm³, 2 cm³, and 5 cm³, are illustrated for the various adjacent organs such as the bladder (neck), rectum (anus), sigmoid, and small bowel (see Section 8.4.1). The two panels show the different locations of the 0.1 cm³ and 2 cm³ reference volumes in the adjacent OARs [modified from GEC ESTRO Recommendations II; see also Westerveld *et al.* (2013)]. Reference points are indicated for the bladder (ICRU, 1985), the rectum and upper vagina (ICRU, 1985), and the mid- and lower vagina (PIBS \pm 2 cm). The vaginal reference length (VRL) (PIBS to midpoint between the vaginal sources) can serve as an indicator to assess the varying position of the vaginal sources relative to the surrounding normal-tissue structures (Westerveld *et al.*, 2013).



BRACHYTHERAPY : EVOLUTION APPLICATORS

*The slides in this section are courtesy of
Dr. Primoz Petric and Prof. Richard Poetter.*



The “systems”



Gosta Forssell
Stockholm System



Claude
Regaud
Paris
System



M.C.Todd
W.J. Meredith
Manchester
System





Intracavitary systems




Edith Quimby
Quimby System

R. Paterson &
H.M Parker
Manchester
System



B .Pierquin &
A. Dutreix
Paris System



Interstitial systems

Historical Paris Technique

1910-1920: Curie Institute, Paris, France



BURDWAN
MEDICAL COLLEGE

Applicator:

Rubber tandem

Cork colpostats
(paraffin coated)

not connected

no fixed
geometry

Distance – colpostats: not fixed


^{226}Ra preloading

X mg of ^{226}Ra for Y hours

Typical application

≈ 5 days (120 h)

7000-8000 mgh



GEC ESTRO Handbook of Brachytherapy




Claude
Regaud

Classical Stockholm method

1913-1914: Radiumhemmet, Stockholm, Sweden



BURDWAN
MEDICAL COLLEGE



Applicator:

Flat box (plate)

Flexible tube

not connected → No fixed geometry

^{226}Ra preloading

● X mg of ^{226}Ra for Y hours

Typical treatment

- 2 – 3 applications (à 20-30 h)
- ≈ 7000 mgh




Gosta Forssell

Historical Manchester System






BURDWAN
MEDICAL COLLEGE

Related to historical Paris technique



TYPICAL TREATMENT:
140 hours for 7500 R at point A
(dose rate 53 R/h)

^{226}Ra preloading (mg):



Given tumour volume

A set of rules

- Geometry
- mg of ^{226}Ra
- Duration

Certain point A dose



Modern Intracavitary Techniques

Applicators: mimicking historical geometries



BURDWAN
MEDICAL COLLEGE

Manchester / Fletcher style





Common features:

Uterine Tandem:
various lengths,
angles or curvatures



Ovoids, cylinders, rings
various outer & source
path diameters

Clamp


Stockholm style



Applicator selection based on tumour topography




Applicator selection based on tumour topography



Advanced brachytherapy applicators



BURDWAN
MEDICAL COLLEGE





BRACHYTHERAPY : EVOLUTION DOSIMETRY

2 D BT

Clinical

Traditional IC

Insertion, packing

Orthogonal X Rays

Not possible

X Ray markers

Point A, B, ICRU Bladder,
Rectal points

Standard loading, MO

Doses to Point A, B, ICRU
Bladder, Rectal points

LDR / HDR / PDR

Preplanning

Applicator selection

Brachy procedure

Imaging

Contouring

Applicator
reconstruction

Definition of dose points

Planning

Plan Evaluation

Treatment delivery

Clinical + MR
Adaptive

MR compatible
IC, IC+IS, IS

Protocols, USG guided
insertion, packing

MR (CT)

Vital – Target, OARs

Dedicated protocols,
applicator commissioning

Point A, ICRU Bladder,
Rectovaginal points


Standard loading, MO,
GO, IP

GYN GEC ESTRO DVH, LQ
spreadsheet, EQD2


HDR / PDR

3 D IGABT


Optimal geometry



Ideal application
Longest tandem
Largest ovoids
Perfect pear




Poor application
Shorter tandem
Largest ovoids
Flattened pear




Poor application
Longest tandem
Smaller ovoids
Narrowed pear


Optimal geometry



Ideal application
and dose distribution



Inappropriate application
and resultant
dose distributions





Physicist

Brachytherapy Planning

Physician


Golden Rule

Good planning and optimization
cannot turn a poor insertion
into a great plan!

MRI images



BURDWAN
MEDICAL COLLEGE



Steps of brachytherapy planning

1

- Applicator reconstruction
Manual, library based

2

- *Standard loading*
 - Based on known loading patterns from systems

3

- Normalization to *a point*
 - *Planning aim vs Prescribed dose*

4

- Plan *Optimization*
 - *Methods*

LQ spreadsheet



BURDWAN
MEDICAL COLLEGE

PHYSICAL - BIOLOGICAL DOCUMENTATION OF GYNAECOLOGICAL HDR BT									
PATIENT , ID-number								tumour entity	
EXTERNAL BEAM THERAPY								FIGO, TNM	
dose per fraction	1.8	TUMOUR		OAR					
fractions without central shield	25	D _{ure} [$\alpha/\beta=10$ Gy]		D _{ure} [$\alpha/\beta=3$ Gy]					
fractions with central shield		44.3		43.2					
total dose	45.0	0.0		0.0		GTV at diag. cm ³			
Total volume (body contour) treated to 43 Gy [cm ³]						chemoth.			
Total volume (body contour) treated to 57 Gy [cm ³]									
BRACHYTHERAPY		F 1	F 2	F 3	F 4	F 5	F 6	dose values in Gy	
date									
physicist									
MR / CT	MRI							TOTAL BT	TOTAL BT + EBT
applicator(s): type, # needles								mean	stddev
applicator(s): dimensions									
Plan, remarks									
TRAK [cGy at 1m]								0.00	
TRAK intrauterine [%]									
TRAK vaginal [%]									
TRAK interstitial [%]									
Planning aim for D ₉₅ CT									
planning aim EQD2 ₁₀									44.3
dose to + A left									74.0
A _{left} EQD2 ₁₀									74.0
dose to - A right									74.0
A _{right} EQD2 ₁₀									74.0
dose to A mean									#VALUE!
A _{mean} EQD2 ₁₀									0.0
GTV _{res} [cm ³]									44.3
D ₉₅									0.0
D ₉₅ EQD2 ₁₀									44.3
CTV _{HR} [cm ³]									0.0
D ₉₅									44.3
D ₉₅ EQD2 ₁₀									44.3
D ₉₀									83.6
D ₉₀ EQD2 ₁₀									44.3
D ₅₀									0.0
D ₅₀ EQD2 ₁₀									44.3
CTV _{IR} [cm ³]									0.0
D ₉₅									44.3
D ₉₅ EQD2 ₁₀									44.3
D ₉₀									44.3
D ₉₀ EQD2 ₁₀									44.3
BLADDER [cm ³]									0.0
Bladder reference point									43.2
ICRU EQD2 ₃									43.2
D _{0.1cm}									43.2
D _{0.1cm} EQD2 ₃									79.3
D _{2cm}									0.0
D _{2cm} EQD2 ₃									0.0
RECTUM [cm ³]									43.2
Recto-vaginal reference point									43.2
ICRU EQD2 ₃									43.2
D _{0.1cm}									43.2
D _{0.1cm} EQD2 ₃									72.1
D _{2cm}									0.0
D _{2cm} EQD2 ₃									0.0
SIGMOID [cm ³]									0.0

*Summation of EBRT
and Brachytherapy
doses by EQD2*

Reporting and auditing

Level 3: *Research-oriented reporting*

All that is reported in Level 1 and 2 plus

Absorbed-dose reporting for the tumor:

- $D_{98\%}$, $D_{90\%}$ for the CTV_{IR} even if not used for prescription
- $D_{90\%}$ for the GTV_{res}
- DVH parameters for the PTV
- $D_{50\%}$ for pathological lymph nodes
- DVH parameters for non-involved nodes (ext/int iliac, common iliac)

OAR volumes and points

- Additional bladder and rectum reference points
- OAR sub-volumes (e.g., trigonum or bladder neck, sphincter muscles)
- Vagina (upper, middle, lower)
- Anal canal (sphincter)
- Vulva (labia, clitoris)
- Other volumes/sub-volumes of interest (e.g., ureter)

Dose–volume reporting for OARs

- Dose–volume and DSH parameters for additional OARs and sub-volumes
- Vaginal dose profiles, dose–volume, and DSHs
- Length of treated vagina

Isodose surface volumes

- 85 Gy EQD2 volume
 - 60 Gy EQD2 volume
-



BRACHYTHERAPY : EVOLUTION OPTIMIZATION

Optimization

- Design a distribution of *source terms* such that the resultant dose distribution satisfies certain constraints and meets certain objectives *as well as possible*.

1. Forward Optimization (FO)

- **Dwell time** – adjust dwell times at each source position
- **Geometric** – based on implant geometry
- **Graphical** – local vs global; drag isodoses

2. Inverse Optimization (IO)

- *IPSA*
- *HIPO*

Brachy Optimization Types

- **Forward – tedious but more robust.**

Generate
plan

Define
objectives

Optimize
plan

- **Inverse – fast but less robust.**

Define
objectives

Optimize
plan

Generate
plan

Optimization

Dwell time → Geometric → Graphical → Inverse

Inverse planning is only relevant when numerous applicators (needles, catheters are used and the planning process by Forward Planning Optimization is complex, laborious and time consuming).

Simulated Annealing

- Simulated annealing (SA) is a *probabilistic technique* for approximating the *global optimum* of a given cost function.
- Specifically, it is a *metaheuristic* to *approximate global optimization in a large search space* for an optimization problem. The technique used is *Stochastic Optimization*.
- For problems where *finding an approximate global optimum is more important than finding a precise local optimum in a fixed amount of time*, simulated annealing may be preferable.
- The name of the algorithm comes from *annealing in metallurgy* (a technique involving heating and controlled cooling of a material to alter its physical properties).

Inverse Planning Simulated Annealing

- CT-based **inverse planning**.
- Produce an optimized plan **in a very short time**.
- Uses **stochastic optimization** only.
- Used for prostate (permanent implants, HDR), breast.
- Dose coverage of PTV (V100) **lower**.
- Dose homogeneity Index **lower**.
- **Overloading of needle ends, higher active length, redundant dwell positions.**
- **DVH parameters often suboptimal.**

Hybrid Inverse Planning Optimization

- CT-based **inverse planning**.
- Produce an optimized plan **in a very short time**.
- Uses both **stochastic and deterministic optimization**.
- Used for prostate, breast, gynaecological implants.
- Dose coverage of PTV (V100) **higher**.
- Dose homogeneity Index **higher**.
- **Overloading of needle ends, higher active length, redundant dwell positions.**
- **DVH parameters better and comparable to FO.**

FO vs IPSA vs HIPO

Strahlenther Onkol (2019) 195:991–1000
<https://doi.org/10.1007/s00066-019-01513-x>

ORIGINAL ARTICLE



BURDWAN
MEDICAL COLLEGE

Dosimetric comparison of inverse optimisation methods versus forward optimisation in HDR brachytherapy of breast, cervical and prostate cancer

Georgina Fröhlich^{1,2} · Gyula Geszti² · Júlia Vízkeleti¹ · Péter Ágoston¹ · Csaba Polgár^{1,3} · Tibor Major^{1,3}




Fig. 1 Dose distributions using HIPO (hybrid inverse planning optimisation), IPSA (inverse planning simulated annealing) and forward optimisation (FO) in interstitial BT (brachytherapy) of breast (a), cervical (b) and prostate (c) cancer. Red dots: active dwell positions (volumes: red: PTV [planning target volume]; a green: non-target breast, blue: ipsilateral lung, pink: ribs; b yellow: bladder, green: rectum, violet: sigmoid, pink: vagina; c yellow: urethra, green: rectum)

Cath.#	Ch.#	Name	0	...	10	...	20	...	30	...	40
1	1	HIPO 1	1	2	3	4	5	6	7	8	9
2	3	HIPO 2	1	2	3	4	5	6	7	8	9
3	4	HIPO 3	1	2	3	4	5	6	7	8	9
4	5	HIPO 4	1	2	3	4	5	6	7	8	9
5	6	HIPO 5	1	2	3	4	5	6	7	8	9
6	7	HIPO 6	1	2	3	4	5	6	7	8	9






Fig. 2 The absolute volume irradiated by 100% of the prescribed dose (V_{100}) using HIPO (hybrid inverse planning optimisation), IPSA (inverse planning simulated annealing) and forward optimisation (FO) methods in interstitial cervical BT (brachytherapy) plans

IMAGE-GUIDED RADIOTHERAPY FOR CERVIX CANCER: HIGH-TECH EXTERNAL BEAM THERAPY VERSUS HIGH-TECH BRACHYTHERAPY

DIETMAR GEORG, PH.D., CHRISTIAN KIRISITS, PH.D., MARTIN HILLBRAND, M.Sc.,
JOHANNES DIMOPOULOS, M.D., AND RICHARD PÖTTER, M.D., PH.D.




Conclusions

For image-guided cervix cancer treatments, both **IMRT** and **IMPT** seem to be inferior to BT.



Thank You



drabhishekbasu@yahoo.com